MRS. KATHERINE ANN THOMPSON, M.A. SLP-CF
Speech Language Pathology in Houston, TX

License number
Texas 106742
Category
Speech Language Pathology
Type
Speech-Language Pathologist
Address
Address
8323 Fwy SW SUITE 101, Houston, TX 77074
Phone
(713) 772-1400
(713) 772-7116 (Fax)
(832) 630-4429

Professional information

Katherine Hegmann Thompson Photo 1

Katherine Hegmann Thompson, Houston TX

Specialties:
Medical Genetics, Clinical Genetics, M.D., Clinical Cytogenetic, Pediatric Medical Genetics, Diagnostic Ultrasound
Work:
Center For Medical Genetics
7400 Fannin St, Houston, TX 77054
Education:
Medical College of Wisconsin (1990)


Katherine H Thompson Photo 2

Dr. Katherine H Thompson, Houston TX - MD (Doctor of Medicine)

Specialties:
Pediatrics, Clinical Cytogenetics, Clinical Genetics
Address:
Center For Medical Genetics
7400 Fannin St STE 700, Houston 77054
(713) 790-1990 (Phone)
Certifications:
Clinical Cytogenetics, 2007, Clinical Genetics, 2007, Pediatrics, 1995
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
Center For Medical Genetics
7400 Fannin St STE 700, Houston 77054
Houston Northwest Medical Center
710 Fm 1960 Rd West, Houston 77090
Memorial Hermann Healthcare System - Southwest
7600 Beechnut St, Houston 77074
Education:
Medical School
Medical College Of Wisconsin
Graduated: 1990


Katherine A Thompson Photo 3

Katherine A Thompson, Houston TX

Specialties:
Speech-Language Pathology
Address:
8323 Southwest Fwy STE 101, Houston 77074
(713) 772-1400 (Phone), (713) 772-7116 (Fax)
Languages:
English


Katherine Thompson Photo 4

Methods And Systems To Determine Fetal Sex And Detect Fetal Abnormalities

US Patent:
2008010, May 8, 2008
Filed:
Oct 9, 2007
Appl. No.:
11/869064
Inventors:
Katherine Thompson - Houston TX, US
International Classification:
C12Q 1/68, A61B 8/13
US Classification:
435006000, 600443000
Abstract:
Non-invasive methods for determining the sex of a human fetus and predicting other genetic abnormalities are disclosed. The methods include screening a maternal sample for biomarkers known to be associated with risk of genetic abnormalities; removing all or substantially all nucleated and anucleated cell populations from the maternal sample to obtain a remaining material; detecting in the remaining material, the presence of nucleic acid; and determining the sex of the fetus from the nucleic acid wherein the presence of a certain marker is indicative of a male fetus; performing an ultrasound scan which yields quantitative measurements of the fetus; and interpreting the results of the genetic abnormality screening in conjunction with the ultrasound measurements.